Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
tau
Biotech
Roche tosses out $120M tau prospect, returning rights to UCB
Roche is walking away from a $120 million bet on the Alzheimer’s disease drug candidate on the cusp of the release of phase 2a data.
Nick Paul Taylor
Oct 22, 2024 8:30am
Potential new Alzheimer's drugs target tangles of tau
Sep 19, 2024 2:42pm
Quanterix launches prescription blood test for Alzheimer's
Jul 10, 2023 9:54am
Proclara gets $47M to target protein misfolding in Alzheimer’s
Sep 7, 2016 7:00am
